Once-daily oral icotrokinra outperforms placebo in ulcerative colitis

For patients with moderately to severely active ulcerative colitis, oral icotrokinra, a peptide that blocks the interleukin-23 receptor, yields a clinical response at week 12 significantly more often than placebo, according to a study published in the Oct. 15 issue of the New England Journal of Medicine.

Read it at Medical Xpress ↗

← Front page